CP-547632 hydrochloride is a well-tolerated, orally-bioavailable ATP-competitive kinase inhibitor. It is currently in clinical trials for the treatment of human malignancies.
CP-547632 is a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 = 11 and 9 nM, respectively). The compound CP-547632 inhibits VEGF and basic FGF-induced angiogenesis in animal models, and inhibits growth of xenograft tumors in mice.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.